Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

ADAM17 inhibition may exert a protective effect on COVID-19

(2020) Vanesa Palau et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs

(2020) Tsvetoslav Georgiev   RHEUMATOLOGY INTERNATIONAL

Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

(2020) Jehun Song et al.   RHEUMATOLOGY INTERNATIONAL

Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era

(2017) Edward M. Behrens et al.   Arthritis & Rheumatology

The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review

(2016) Cecilia Beatrice Chighizola et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir

(2014) Javier Carbajo-Lozoya et al.   VIRUS RESEARCH

Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROS-induced and metalloproteinase-dependent EGF-receptor signaling

(2011) El-Sayed Akool et al.   BIOCHEMICAL PHARMACOLOGY

Cyclosporin A inhibits the replication of diverse coronaviruses

(2011) A. H. de Wilde et al.   JOURNAL OF GENERAL VIROLOGY